Niall Hodgins, Co-Founder and CEO of SeraNovo, has dedicated his career to significant advances in formulation technology. A graduate in Chemistry from the University of Bath and Leiden University, his strong research capabilities have led to a range of patents. He is the co-inventor of SeraNovo's unique technology. Over the past seven years, he has transformed SeraNovo into a globally recognized company, specializing in the formulation of small molecules and peptides.

Josh Horvath is the Head of Device Engineering at Genentech in South San Francisco, CA where he leads a team of engineers and scientists responsible for developing novel medical device/combination product technologies.  He joined Genentech in 2013 and previously spent seven years with Becton Dickinson in a variety of R&D and product development roles.  He is listed as an inventor on 45+ issued U.S. patents and is the author or co-author of more than 20 peer-reviewed journal articles.  Josh holds a B.S. in Chemical Engineering from the University of Florida and a Ph.D. in Chemical Engineering from Carnegie Mellon University. 

As a Partner at PA Consulting in the Global Health and Life Sciences Team, Kate Hudson-Farmer leads both early and later stage strategic initiatives, with a strong focus, but not limited to, drug delivery and connected health. Designed to add value and competitiveness to products and services, and enrich the end to end product development offering from PA Consulting.

Chris Hurlstone joined Team Consulting in 1994 with a mechanical engineering background in the offshore industry and now has almost thirty years of product innovation experience in the healthcare sector. He combines technical input and review with business development, management and leadership activities. His experience covers all stages of product life cycle from direction-setting to post-launch support, working with companies ranging from small start-ups to large multinational organizations. Mr Hurlstone has particular expertise in the design, development and industrialization of drug delivery devices including dry powder and pressurized metered dose inhalers and injection systems including pen injectors, auto-injectors, needle-free injectors and on-body delivery systems. He has also worked on the development of surgical, diagnostic and medtech products and systems. Mr Hurlstone has extensive experience in the field of engineering analysis, design verification and risk management and has written and presented articles and papers on many aspects of device development. In his previous role of Director of Engineering, he was responsible for the ongoing quality and continuous improvement of Team’s overall engineering offering including mechanical, electro-mechanical, electronics and software engineering and applied science. In his current role of Technical Director he works more broadly across all discipline groups including Design, Human Factors, Device Testing and Programme Management, to help ensure consistent excellence of project delivery for all of Team's clients.

Combining a strong medical background with extensive experience in digital healthcare, Radu Iancu is the Founder and CEO of KeborMed, a company at the forefront of medtech and pharma device connectivity. Leveraging his PhD in Biomedical Engineering from Case Western Reserve University and his expertise as a cardiologist, Dr Iancu continues to innovate and elevate the field of healthcare technology, with a sharp focus on improving patient outcomes. Throughout his career, Dr Iancu has been a significant contributor to the digital strategy for Fortune 500 companies and has helped propel various startups to new heights. Currently, he and his team at KeborMed continue to shape the future of healthcare technology, demonstrating the transformative potential of digital health.

Dr Stefanie Johns brings over 12 years of comprehensive regulatory experience across medical devices, pharmaceuticals, biologics, and combination products. Stefanie has provided strategic global regulatory guidance from concept through commercialization and life cycle management. Previously, Dr Johns served as Chief Scientific Officer at Hoth Therapeutics where she contributed to the invention and development of several therapeutic drug and diagnostic products. Dr Johns served as Director of Regulatory Affairs at Enable Injections, a device-constituent part developer and manufacturer of large-volume on-body infusion systems. As Scientific and Regulatory Manager at Camargo Pharmaceutical Services, Dr Johns provided strategic guidance on over 20 different drug-device combination product programs spanning therapeutic divisions at CDER and CDRH. Early in her career, Dr Johns assisted with the Integrity of Supply Initiative including members of the FDA and Senate HELP Committee Staff as the Program Manager of Xavier Health Initiatives. Dr Johns, graduated from the University of Cincinnati College of Medicine with a Doctorate degree in Molecular Genetics, Biochemistry, and Microbiology. She graduated from the Wright State University magna cum laude with a Bachelor’s degree in Biological Sciences.

Eduardo Jorgensen studied medicine, with special interest in Neurosurgery until a young girl with diabetes refused to keep injecting insulin because she had a poor quality of life. He then moved from the clinical path to medical innovation, creating 3 products for chronic diseases and obtaining recognition as the Spanish innovator of the year by MIT or the Forbes 30 under 30. He spends his free time in music festivals and taking care of two Sulcata Tortoises.

Rasmus Just joined Novo Nordisk in 2022 as Vice President, Device Innovation. In this role he is overall responsible for research and innovation activities to support future delivery solutions. Before Novo Nordisk, Mr Just held various leadership positions within the medical device industry. He has worked within MedTech innovation and development, helping people with intimate healthcare needs, developing a broad range of devices from single use disposables and electro-mechanical durables to implants and surgical instruments. Mr Just holds a MSc in Applied Mechanics and an eMBA in Management of Technology and serves as an external examiner at several universities and research institutions.

Asmita Khanolkar has a Master’s degree in Materials Science & Engineering from Worcester Polytechnic Institute in Worcester, MA, USA. She has over 25 years of manufacturing experience, with specialization in the Medical Device and Pharmaceutical industry. She has managed various device projects at various stages from concept to commercial launch. Her product portfolio includes single-use, wearable and implantable devices, drug-device, device- biologic combination products for drug delivery, cell therapy, biotech, bio therapeutics and pharmaceutical applications. She has held various engineering and management roles in New Product Development, Manufacturing Engineering, Advanced Quality Planning, Operations, Supply Chain and Product Life Cycle Management. Her current responsibilities include a corporate leadership role supporting multiple sites for bringing complete solutions to the customers, working closely within the Oval Medical Technologies, Cambridge Pharma and SMC Ltd. global sites in early technical engagement through commercialization for combination products and pharmaceutical services.

For the last 35 years, Ramesh Kashi has been involved in the development of diverse biologics drugs and modalities including Clotting Factors, Autologous Cancer Vaccines, Targeted Radiotherapies, Checkpoint Inhibitors, Antibody Drug Conjugates, Monoclonal and Multi-Specific Antibodies, Gene Therapies etc. He has held scientific leadership and advisory positions in large pharma, mid-sized biotech, start-up companies and was involved in development of three marketed therapeutic protein medicines for the treatment of cancer, auto-immune and hemophilia. He is passionate about evaluating external innovation and technologies and internalizing them for the development of high concentration protein formulations to enable delivery of large doses by subcutaneous route of administration.